Skip to Content

Dienogest / estradiol Pregnancy and Breastfeeding Warnings

Dienogest / estradiol is also known as: Natazia

Dienogest / estradiol Pregnancy Warnings

Use is contraindicated. AU TGA pregnancy category: B3 US FDA pregnancy category: Not assigned Comments: -Discontinue this drug if pregnancy occurs. -Consider the increased risk of venous thromboembolism when restarting this drug during the postpartum period. -Women who are not breastfeeding may start this drug no earlier than 4 weeks postpartum.

Animal studies do not indicate teratogenicity. There are no controlled data in human pregnancy. There is little or no increased risk of birth defects if this drug is inadvertently used during early pregnancy. Epidemiological studies and meta-analyses have not found an increased risk of genital or non-genital birth defects AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Dienogest / estradiol Breastfeeding Warnings

Use is not recommended. Excreted into human milk: Yes Comments: -If possible, use of other forms of contraception until the child is weaned. -Estrogen containing combined oral contraceptives reduce milk production, which is less likely once breast feeding is well established, as well as change the composition of breast milk. -Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk, which may affect the child.

See references

References for pregnancy information

  1. "Product Information. Natazia (dienogest-estradiol)." Bayer Pharmaceutical Inc, West Haven, CT.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Natazia (dienogest-estradiol)." Bayer Pharmaceutical Inc, West Haven, CT.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.